Stay updated on Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page
- Check2 days agoChange DetectedThe page’s platform/site revision label was updated from **v3.5.2** to **v3.5.3**, reflecting a behind-the-scenes release rather than a change to the clinical trial record.SummaryDifference0.1%

- Check9 days agoChange DetectedAdded revision: v3.5.2; removed revision: v3.5.0.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check38 days agoChange DetectedRevision label updated from v3.4.3 to v3.5.0 on the page.SummaryDifference0.1%

- Check52 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check74 days agoChange DetectedThe site version badge updated from v3.4.1 to v3.4.2, indicating a backend/frontend revision. No study content or functionality was changed as part of this update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check81 days agoChange DetectedThe only visible change is the footer revision updated from v3.4.0 to v3.4.1, and the main content remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page.